Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731094 | 0.84 | LOX (0.39) | EPAS1GBA1KAT6ANR1H2NR1H3 | |
| SCHEMBL13731063 | 0.82 | MAPT (0.47) | — | |
| SCHEMBL13730724 | 0.81 | MAPT (0.41) | EPAS1NR1H2NR1H3LOX | |
| SCHEMBL25405123 | 0.80 | EPAS1 (0.37) | EPAS1GBA1KAT6ANR1H2NR1H3 | |
| SCHEMBL13732231 | 0.79 | ALDH1A1 (0.39) | GBA1KAT6ALOX | |
| SCHEMBL3054211 | 0.78 | SOD1 (0.40) | — | |
| SCHEMBL13730661 | 0.78 | ADRB2 (0.40) | GBA1KAT6A | |
| Mesdopetam SCHEMBL13732678 | 0.78 | KAT6A (0.40) | GBA1KAT6A | |
| Mesdopetam SCHEMBL29438806 | 0.78 | KAT6A (0.40) | GBA1KAT6A | |
| Mesdopetam SCHEMBL29438808 | 0.78 | KAT6A (0.40) | GBA1KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699543-B1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2016-03-02 | — | — | EP | disclosed |
| US-9120728-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-20150148426-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-05-28 | — | — | US | disclosed |
| US-9006227-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Swenden AB (SE) | 2014-05-08 | — | — | US | disclosed |
| EP-2699543-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143337-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | NEUROSEARCH A/S (DK) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | GRIN3A, GRIN1, GRIN3B | EPAS1 4195/4885GBA1 1423/4885KAT6A 795/4885 |
| US-20150148426-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | GRIN3A, GRIN1, GRIN3B | EPAS1 4195/4885GBA1 1423/4885KAT6A 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.